Learn more about whether ACADIA Pharmaceuticals Inc. or Sarepta Therapeutics, Inc. is a better investment based on AAII's A+ ...

again leading to a loss of market share. Medicare has also selected NVO’s semaglutide medicines for the second round of price negotiations in 2025, which is likely to negatively impact the ...

AbbVie's strategic move into the obesity market through a partnership with Gubra A/S shows potential but won't impact revenue ...

From its January 2010 inception through the end of October 2024, the A share class' annualized return of 6.9%(in GBP) is ahead of its OECD G7 Consumer Price ... positions in Catalent, Amazon.com ...

The portfolio can look aggressive by many measures, with average price multiples and growth rates ... from coronavirus-related spending, such as Catalent and West Pharmaceutical Services, suffered ...

Novo Nordisk NVO shares have lost 21% in the past three months against the industry’s growth of 4.6%. The company has also ...

CALGARY — Oil and gas producers Whitecap Resources Inc. and Veren Inc. are joining forces in a $15-billion deal to create the ...

Donald Trump’s incoming administration was promising to slash corporate taxes and tear up red tape in the world’s mightiest ...

Shares of Veren rose more than 15% to 8.15 Canadian dollars ($5.67) after the company agreed to merge with Whitecap Resources in a C$15 billion deal that will enlarge its Alberta oil and gas footprint ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Infosys is a part of multiple indices like Nifty 50, Nifty 500, S&P BSE Sensex etc. Infosys Ltd share price was up by 1.66% from the previous closing price of ₹1,686.00. Who are peers of Infosys ...

The transaction – first announced in February – would see Novo Nordisk's parent company Novo Holdings buy contract development and manufacturing organisation (CDMO) Catalent outright for $16.5 ...